Epizyme, Inc. (EPZM) Sets New 1-Year High on Insider Buying Activity

Shares of Epizyme, Inc. (NASDAQ:EPZM) reached a new 52-week high on Tuesday following insider buying activity. The stock traded as high as $18.95 and last traded at $19.15, with a volume of 661,356 shares traded. The stock had previously closed at $17.85.

Specifically, CFO Andrew E. Singer sold 3,024 shares of the stock in a transaction on Friday, June 30th. The stock was sold at an average price of $15.50, for a total transaction of $46,872.00. Following the completion of the transaction, the chief financial officer now directly owns 40,529 shares of the company’s stock, valued at $628,199.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director David M. Mott acquired 200,000 shares of Epizyme stock in a transaction on Monday, September 18th. The shares were purchased at an average cost of $15.25 per share, with a total value of $3,050,000.00. Following the completion of the acquisition, the director now owns 6,000 shares of the company’s stock, valued at approximately $91,500. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 48,024 shares of company stock valued at $706,722. 25.20% of the stock is owned by corporate insiders.

EPZM has been the subject of several research reports. BidaskClub raised Epizyme from a “sell” rating to a “hold” rating in a report on Thursday, August 24th. Oppenheimer Holdings, Inc. set a $26.00 price objective on Epizyme and gave the company a “buy” rating in a report on Monday, June 5th. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Epizyme in a report on Wednesday, June 7th. Royal Bank Of Canada reissued a “buy” rating and set a $20.00 price objective on shares of Epizyme in a report on Friday, September 15th. Finally, ValuEngine lowered Epizyme from a “hold” rating to a “sell” rating in a report on Saturday, June 3rd. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $23.33.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.08. Epizyme had a negative net margin of 1,376.33% and a negative return on equity of 63.10%. The firm had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.95 million. During the same quarter in the previous year, the firm posted ($0.49) EPS. The company’s revenue for the quarter was up 2027.7% compared to the same quarter last year.

Hedge funds have recently modified their holdings of the company. Legal & General Group Plc grew its position in shares of Epizyme by 8.9% during the 1st quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock valued at $165,000 after acquiring an additional 795 shares during the period. UBS Asset Management Americas Inc. bought a new stake in shares of Epizyme during the 1st quarter valued at $175,000. BB&T Securities LLC bought a new stake in shares of Epizyme during the 2nd quarter valued at $181,000. Trexquant Investment LP bought a new stake in shares of Epizyme during the 2nd quarter valued at $184,000. Finally, SG Americas Securities LLC grew its position in shares of Epizyme by 83.3% during the 2nd quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock valued at $202,000 after acquiring an additional 6,072 shares during the period. 83.74% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/09/21/epizyme-inc-epzm-sets-new-1-year-high-on-insider-buying-activity.html.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply